Eli Lilly has established itself as a leader in the rapidly growing GLP-1 market. The U.S. incretin market grew by an impressive 45% in the fourth quarter of 2024, underscoring the significant ...

LifeMD is a fast-growing, profitable telehealth company with strong partnerships. Click here to read why LFMD stock is a Buy.

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...

Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

U.S. stock indexes rallied on Monday as investors looked past worries of potential crude supply disruptions after the United ...

IRFC shares opened the week on the back foot, slipping to ₹133.50 in early trade before edging back toward ₹136. The stock is ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

The stock's fall snapped a four-day winning streak.

Eli Lilly and Company (NYSE:LLY) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 ...